BioSyent, Inc. (RX) Stock Analysis | Price, Returns, Financials & Key Metrics

Mojo Score Change: BioSyent, Inc. has changed its score on 27 Nov 2025. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.08 k

Shareholding (Mar 2025)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

High Management Efficiency with a high ROE of 18.15%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 7.50

Positive results in Mar 25

With ROE of 21.97%, it has a very attractive valuation with a 3.43 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 129 Million (Small Cap)

P/E

16.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.54

Return on Equity

21.97%

Price to Book

3.42

Revenue and Profits:

Net Sales:

10 Million

(Quarterly Results - Jun 2025)

Net Profit:

2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-0.71%

6 Months

2.75%

1 Year

6.22%

2 Years

42.26%

3 Years

65.97%

4 Years

43.11%

5 Years

70.71%

BioSyent, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

BioSyent Adjusts Valuation Amid Strong Financial Performance and Growth Indicators

BioSyent, Inc., a small-cap pharmaceutical company, has recently experienced an evaluation adjustment reflecting its strong financial profile. Key metrics include a 21.97% return on equity, impressive operating cash flow of CAD 8.92 million, and a favorable return on capital employed, highlighting its solid market position and financial health.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

11.80%

EBIT Growth (5y)

8.45%

EBIT to Interest (avg)

7.50

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.48

Sales to Capital Employed (avg)

0.94

Tax Ratio

25.74%

Dividend Payout Ratio

29.49%

Pledged Shares

Institutional Holding

ROCE (avg)

100.69%

ROE (avg)

18.15%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.43

EV to EBIT

10.78

EV to EBITDA

10.01

EV to Capital Employed

6.25

EV to Sales

2.76

PEG Ratio

0.83

Dividend Yield

ROCE (Latest)

57.94%

ROE (Latest)

21.97%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -7.27% vs 25.00% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -13.04% vs 43.75% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10.20",
          "val2": "11.00",
          "chgp": "-7.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.80",
          "val2": "3.20",
          "chgp": "-12.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.00",
          "val2": "2.30",
          "chgp": "-13.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "252.10%",
          "val2": "268.60%",
          "chgp": "-1.65%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 10.76% vs 13.26% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 12.31% vs 18.18% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "35.00",
          "val2": "31.60",
          "chgp": "10.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9.20",
          "val2": "8.00",
          "chgp": "15.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "7.30",
          "val2": "6.50",
          "chgp": "12.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "246.50%",
          "val2": "238.50%",
          "chgp": "0.80%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

10.20

11.00

-7.27%

Operating Profit (PBDIT) excl Other Income

2.80

3.20

-12.50%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

2.00

2.30

-13.04%

Operating Profit Margin (Excl OI)

252.10%

268.60%

-1.65%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -7.27% vs 25.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -13.04% vs 43.75% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

35.00

31.60

10.76%

Operating Profit (PBDIT) excl Other Income

9.20

8.00

15.00%

Interest

0.10

Exceptional Items

0.00

Consolidate Net Profit

7.30

6.50

12.31%

Operating Profit Margin (Excl OI)

246.50%

238.50%

0.80%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 10.76% vs 13.26% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 12.31% vs 18.18% in Dec 2023

All Annual Results

Company CV

About BioSyent, Inc.

BioSyent, Inc.

Pharmaceuticals & Biotechnology

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused on improving family and women's health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. Cathejell is indicated for surface anesthesia and lubrication for various procedures. RepaGyn helps relieve dryness and promotes healing of the vaginal mucosa. It also manufactures and markets Protect-It, a non-toxic product.

Company Coordinates

Company Details

170 Attwell Dr Suite 520 , ETOBICOKE ON : M9W 5Z5

Tel: 1 905 2060013

http://www.biosyent.com

Registrar Details

BioSyent, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

High Management Efficiency with a high ROE of 18.15%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 7.50

Positive results in Mar 25

With ROE of 21.97%, it has a very attractive valuation with a 3.43 Price to Book Value

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

BioSyent Adjusts Valuation Amid Strong Financial Performance and Growth Indicators

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About BioSyent, Inc.

Company Coordinates